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Abstract
Background: Sigma-2 receptors are over-expressed in proliferating cancer cells, making an attractive target for the
targeted treatment of pancreatic cancer. In this study, we investigated the role of the novel sigma-2 receptor
ligand SW43 to induce apoptosis and augment standard chemotherapy.
Results: The binding affinity for sigma-2 ligands is high in pancreas cancer, and they induce apoptosis with a rank
order of SV119 < SW43 < SRM in vitro. Combining these compounds with gemcitabine further increased apoptosis
and decreased viability. Our in vivo model showed that sigma-2 ligand treatment decreased tumor volume to the
same extent as gemcitabine. However, SW43 combination treatment with gemcitabine was superior to the other
compounds and resulted in stabilization of tumor volume during treatment, with minimal toxicities.
Conclusions: This study shows that the sigma-2 ligand SW43 has the greatest capacity to augment gemcitabine in
a pre-clinical model of pancreas cancer and has provided us with the rationale to move this compound forward
with clinical investigations for patients with pancreatic cancer.
Background
Pancreatic cancer is the fourth leading cause of cancer
related mortalities with an overall five-year survival rate of
five percent [1]. Randomized controlled trials have demon-
strated modest prolongation of patient survival with che-
moradiation or chemotherapy [2-6] and gemcitabine has
become standard therapy as a single agent or in combina-
tion with other therapies depending on stage [2,5,7].
While results from standard therapies offer some moder-
ate prolongation of survival, novel treatment options are
desperately needed. Sigma-2 ligands have been investi-
gated for their therapeutic role in the treatment of cancers,
and we have previously shown sigma-2 receptor overex-
pression in Panc02 tumor bearing C57BL/6 mice and an
increased survival in this model by treatment with novel
sigma-2 ligands [8,9]. These compounds offer promising
potential as novel therapeutics for the treatment of solid
tumors, including pancreatic cancer.
Sigma receptors were originally thought to belong to
the family of opioid receptors [10], and initial interest
was in regard to binding of neuropharmaceuticals such
as haloperidol and phenylcyclohexylpiperidine [11,12].
Further study identified two isotypes of the receptor,
sigma-1 and sigma-2, with molecular weights of 25 -
29 kDa and 19 - 21.5 kDa respectively [12-15]. While
the sigma-1 receptor has been identified and cloned
[16,17], the sigma-2 receptor has not been identified.
Because of this, studies have revolved around its phar-
macological properties. Prototypical compounds for
binding studies include [
3H]-(+)-pentazocine [18,19],
with high affinity to sigma-1 and low affinity to sigma-
2, and [
3H]-1,3 di-ortho-tolylguanidine ([
3H]-DTG),
[19] which has equal affinity to both receptors. The
concurrent use of non-labeled (+)-pentazocine with
[
3H]-DTG was classically used to study the binding
affinity of ligands to the sigma-2 receptor [20] and
assisted in their isolation from lipid rafts [21]. Since
then, multiple compounds with higher specificity to
sigma-2 receptors have been used for binding studies
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3H]-RHM-1 [22] and
[
125I]-ISO-2 [23] in our laboratory.
Sigma-1 and -2 receptor ligands bind a wide range of
normal tissues, but early observations showed sigma-2
receptor over-expression in primary colon cancers,
renal carcinomas, and sarcomas [24]. Further studies
showed increased expression of sigma receptors in a
variety of human and rodent cell lines [25]. Since then,
it has been shown that sigma-2 receptors are upregu-
lated in solid tumors and that their presence can be
used as a marker of proliferation, making them an
attractive target for imaging of tumors in vivo [26]. In
addition, multiple studies have shown that several dif-
ferent sigma-2 ligands induce tumor selective cytotoxi-
city and apoptosis, the mechanism of which is
currently poorly understood [9,27-30].
We have identified a sigma-2 ligand, SW43, similar in
structure to the previously studied SV119, with
e n h a n c e da c t i v i t y .W eh a v ep r e v i o u s l ys h o w nt h a t
SV119 specifically binds to sigma-2 receptors and
induces apoptosis in pancreas cancer [8,9]. In this study,
we systematically tested sigma-2 ligands in vitro and
in vivo for relative effectiveness in pancreatic cancer and
their relative toxicity in order to identify the best candi-
date to move into a clinical trial.
Results
Sigma-2 ligands have high affinity for pancreas cancer
and decrease viability
Several groups have shown that sigma-2 specific
ligands decrease viability in cancer cells [27,28,30] and
we have reported that sigma-2 specific ligands induce
apoptosis in pancreas cancer [9]. In this study, we
compared the antitumor effects of the novel sigma-2
receptor ligand SW43 with our previously studied
compound, SV119, and a commercially available
sigma-2 ligand, siramesine (SRM).
The sigma-2 specific ligands SRM and SV119 and
sigma-1 specific ligand pentazocine were compared to
the novel sigma-2 ligand SW43 in characterization of
the pharmacological binding profile to sigma-2 receptors
in Panc02 tumor membrane homogenates. Competitive
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Figure 1 Sigma-2 ligands have high affinity for pancreas cancer and decrease viability. A. Chemical structures of sigma-2 ligands. B.
Representative competitive binding data for inhibition of [
125I]-ISO-2 binding to sigma-2 receptors in Panc02 tumor membrane homogenates.
IC50 for binding affinities are pentazocine 1381 ± 33 nM, siramesine 1.9 ± 0.1 nM, SV119 7.8 ± 1.7 nM, and SW43 18 ± 2.1 nM. C. Pancreas cancer
cell lines were treated with escalating doses of the sigma-2 ligands SV119, SW43, and siramesine (SRM) or DMSO vehicle for 18 hours and
viability relative to vehicle determined by CellTiter-Glo Luminescent Viability Assay (Promega).
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Page 2 of 11binding curves (Figure 1B) show the affinity rank order
for sigma ligands as Siramesine > SV119 ≥ SW43 >>
(+)-pentazocine. The IC50 values (mean ± SEM) for
inhibiting [
125I]-ISO-2 binding to sigma-2 receptors are
pentazocine 1381 ± 33 nM, SRM 1.9 ± 0.1 nM, SV119
7.8 ± 1.7 nM, and SW43 18 ± 2.1 nM.
Multiple human (AsPC1, BxPC3, Cfpac, Panc1, and
MiaPaCa-2) and mouse (Panc02) (Figure 1C) pancreas
adenocarcinoma cell lines were treated with doses of
sigma-2 ligand ranging from 1 to 1000 μM for 18 hours.
To compare the relative effect on viability, IC50 values
for each cell line were calculated (Table 1). The range of
IC50 values was 50-106 μM for SV119, 21-56 μMf o r
SW43, and 11-36 μM for SRM. From these IC50 values,
we observe that the relative cytotoxicity was SRM >
SW43 > SV119.
Sigma-2 ligands induce caspase-3 activation
Sigma-2 ligands have been observed to induce apoptosis
by caspase-3 dependent and independent mechanisms in
several cancer cell lines [9,28,31]. To compare caspase-3
activity induced by SV119, SW43, and SRM, Panc02
mouse adenocarcinoma cells were treated with sigma-2
ligands (25 μM) for 18 hours and assayed for cleavage
of the caspase-3 fluorogenic substrate Ac-DEVD-AMC.
To determine whether this activity was caspase-3 speci-
fic, the caspase-3 inhibitor DEVD-FMK (1 μM) was
applied one hour prior to sigma-2 ligand. SW43 and
SRM similarly increased caspase-3 activity by 2.4 and
2.3 fold (p < 0.001) respectively compared to cells trea-
ted with DMSO vehicle only, while SV119 had little
effect on caspase-3-like activity (p > 0.05) under these
conditions (Figure 2A). Treatment with DEVD-FMK did
not change the effect on viability (Figure 2B) (p > 0.05).
To verify that caspase-3 activity correlates with apopto-
sis, cells were also assayed for extracellular Annexin-V
expression (Figure 2C, D). Expression was increased
from 2 ± 1 percent with vehicle to 7 ± 4 percent for
SV119 (p > 0.05), 40 ± 5 percent for SW43 (p < 0.05),
and 40 ± 11 percent for SRM (p < 0.05).
Sigma-2 ligands generate reactive oxygen species
The mechanism of sigma-2 ligand induced apoptosis is
not well understood and has been shown in different
cells types to be caspase-3 dependent or independent
[9,31,32]. While we have previously shown that sigma-2
ligands can induce caspase-3 in pancreatic cancer cells
[8,9], others have shown SRM increases reactive oxygen
species (ROS) [28,29]. In order to compare these sigma-
2 ligands, we quantified the capacity of SV119, SW43,
and SRM to generate ROS. Panc02 were treated with
sigma-2 ligands (25 μM 18 hrs) or vehicle (Figure 3)
and incubated with 5-(and-6)-carboxy-2’,7’-dichlorodihy-
dro-fluorescein diacetate (carboxy-H2DCFDA) Image-iT
Live Green Reactive Oxygen Species Detection Kit
(Molecular Probes, Eugene, OR) for analysis by flow
cytometry. The oxidation of carboxy-H2DCFDA to
2’,7’-dichlorofluorescein (DCF) leads to detectable fluor-
escence in the FL1channel. We observed that SV119
treatment generated little ROS, while SW43 and SRM
g e n e r a t e dal a r g ea m o u n to fR O S( F i g u r e3 A ) .I no r d e r
to determine whether viability could be rescued with the
lipid antioxidant alpha-tocopherol (a-toco), cells were
pretreated with a-toco (200 μg/mL) for one hour prior
to sigma-2 ligand treatment. Viability was partially res-
cued for SW43 (45% to 61%, p < 0.05) and SRM (32%
to 76%, p = 0.01) in the presence of a-toco, but not for
SV119 (82% to 90%, p > 0.05) (Figure 3B). To establish
whether the rescue of viability by a-toco was through
protection against apoptosis, we quantified the caspase-3
activity and Annexin-V staining (Figure 3C and 3D). We
observed that sigma-2 ligand induced caspase-3 activity
was partially reduced for SW43 (3 fold down to 1.9 fold,
p < 0.01) in the presence of lipophilic a-toco, but was
completely reduced for SRM (5.4 fold down to 0.98 fold,
p = 0.01). Flow cytometry analysis for Annexin-V veri-
fied that induction of caspase-3 activity correlated with
apoptosis (Figure 3D). Apoptosis by SW43 was
decreased from 34% to 14%, p < 0.05, and SRM-induced
apoptosis decreased from 46% to 1.5%, p < 0.05.
Sigma-2 ligands enhance standard chemotherapy by
increasing apoptosis
We have previously reported that sigma-2 ligands
potentiate chemotherapy for pancreatic cancer in vitro
and in vivo (9). Here, we compared viability after SW43
treatment in selected human (Panc1, BxPC3, and Cfpac)
and mouse (Panc02) (Figure 4) pancreas adenocarci-
noma in combination with gemcitabine. These cells
have sufficient variability in sensitivity to gemcitabine to
detect overlapping mechanism of apoptosis by gemcita-
bine or sigma-2 ligand. Cells were treated with gemcita-
bine (500 nM) or vehicle for 24 hours prior to sigma-2
ligand (25 μM) treatment for 18 hours. Gemcitabine
alone decreased viability in our cell lines (range 40 to
Table 1 IC50 (μM) for pancreas cancer cell lines treated
with sigma-2 ligands for 18 hours
Cell Line SV119 SW43 SRM
Panc02 50 ± 9 21 ± 0 11 ± 2
MiaPaCa2 58 ± 8 29 ± 6 17 ± 1
Panc1 64 ± 10 35 ± 3 19 ± 2
Bxpc3 84 ± 17 38 ± 2 19 ± 3
Cfpac 76 ± 14 49 ± 4 16 ± 1
Aspc1 106 ± 7 56 ± 1 36 ± 8
(Mean ± SEM), n ≥ 3
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Page 3 of 1171%, Table 2) compared to vehicle and sigma-2 ligands
were additive to that of gemcitabine in each cell line. To
determine whether decrease in viability was through
enhancement of apoptosis (Additional File 1), Panc02
cells were stained with Annexin-V-FITC conjugated
antibody and propidium iodide (PI). Annexin-V posi-
tive/PI negative cells represent early apoptotic cells and
Annexin-V positive/PI positive cells represent late apop-
totic and necrotic cells. We observed a shift through the
early apoptotic population towards late apoptotic as the
relative strength of the treatment increased. Enhance-
ment of gemcitabine by SW43 was greater than that of
the previously reported compound SV119 (p < 0.01).
Sigma-2 ligands confer a protective effect against
pancreas cancer in vivo
We have previously shown that sigma-2 ligands augment
the antitumorigenic effect of gemcitabine in vivo [9]. Here,
we compared the novel compound SW43 against SV119
and SRM in combination therapy with gemcitabine.
C57BL/6 female mice werei n o c u l a t e dw i t h1×1 0
6
Panc02 cells subcutaneously and 13 days following tumor
injection, when all mice had tumors with a diameter of
approximately 5 mm, mice were randomized into groups
of n = 12-15. Sigma-2 ligands SW43 (1.1 mg), SV119 (1.0
mg), or SRM (1.1 mg) were given by IP injection daily for
two weeks with or without weekly gemcitabine (3.0 mg).
(Figure 5) Following conclusion of treatment (Day 27),
tumors were significantly smaller for individual treatment
groups SW43 (mean = 67 mm
3) and gemcitabine (mean =
76 mm
3) compared to vehicle (mean = 141 mm
3)( p<
0.001). Single agent sigma-2 ligand treated mice had simi-
lar tumor volumes that were statistically similar to gemci-
tabine. However, mice receiving combination therapy of
SW43 and gemcitabine had the smallest tumors (mean =
27 mm
3) (p < 0.001) that, over the entire two week treat-
ment course, stabilized and tumor size on day 13 was
equal to tumor size on day 27. Combination with
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Figure 2 Sigma-2 ligands induce caspase-3 activation in pancreas cancer. Panc02 cells were pre-treated with caspase-3 inhibitor (DEVD-
FMK 1 μM) or DMSO vehicle for one hour prior to exposure to sigma-2 ligands (25 μM) SV119, SW43, siramesine (SRM) or DMSO vehicle for
18 hours. A. Caspase-3 activation was quantified by cleavage of the fluorogenic substrate Ac-DEVD-AMC and expressed relative to vehicle. The
caspase-3 specific inhibitor DEVD-FMK abrogates caspase-3 dependent cleavage. B. Caspase-3 inhibition does not protect cells from sigma-2
ligand induced cell death. C. Flow cytometry for Annexin-V verifies apoptosis by sigma-2 ligand. D. Representative flow cytometry dot plot
showing cells moving from Annexin-V negative quadrant (upper panel) with vehicle towards Annexin-V positive quadrant (lower panel) with
SW43 treatment. (Means ± SEM), n ≥ 3, *p < 0.05, **p > 0.05.
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Page 4 of 11gemcitabine decreased tumor volume further for SW43
(mean = 27 mm
3) compared to SV119 (mean = 43 mm
3)
or SRM (mean = 53 mm
3) (Figure 5C,A, and 5B, respec-
tively). Even though treatment was discontinued on
day 27, sigma-2 ligands also conferred a survival advantage
for mice in this trial. The median survival for mice treated
with DMSO was 46 days compared to 57 days for mice
treated with a combination of SW43 and gemcitabine (p <
0.001). All other treatment groups had a median survival
of 49 to 52 days. One animal from the SW43 and gemcita-
bine combination group had complete regression of the
tumor (data not shown). The initial tumor volume in this
mouse did not differ from the mean of cohorts until two
weeks following treatment (day 42). At this time, the
tumor steadily decreased in volume until it was no longer
palpable by day 51. The local area of tumor growth was
surgically removed when the tumor was no longer palp-
able after two repeated measurements, and histologic
examination confirmed the absence of tumor.
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ligand induced caspase-3 activity was partially reduced for SW43 in the presence of lipophilic a-toco, but completely for SRM. D. Flow cytometry
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Figure 4 Sigma-2 ligands enhance gemcitabine induced cell
death in pancreas cancer. Multiple pancreatic cancer cell lines,
including Cfpac, Panc1, BxPC3 (Table 1), and Panc02 (shown) were
treated with DMSO vehicle or sigma-2 ligands (25 μM) SV119, SW43,
or siramesine (SRM) following 24 hour pre-treatment with
gemcitabine (0.5 μM). Eighteen hours later cell viability was
determined using the CellTiter-Glo Luminescent Viability Assay
(Promega), (mean ± SEM), n ≥ 3.
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Therapeutic window is a concern in treating patients
with chemotherapies. We have previously performed
toxicity profiling for SV119 in vivo and found toxicity to
be negligible [8]. Equimolar amounts of SW43 (1.1 mg)
and SV119 (1.0 mg) were compared in C57BL/6 female
mice by daily treatment for two weeks, with and without
weekly gemcitabine (3 mg). Mice were sacrificed for
blood cytology and serum chemistries (Additional File 2),
and organs for histologic and gross pathology review. Of
note, we observed minor anemia and decreased pancrea-
tic enzyme levels that were statistically different p < 0.05,
but not clinically significant. When combined with gem-
citabine, hemoglobin levels decreased 2.7 g/dL for
SV119, 3.7 g/dL for SV119, and 4.9 g/dL for SW43.
Gross pathology and histology reports of brain, kidney,
liver, and pancreas were not appreciably different from
untreated control animals( d a t an o ts h o w n ) .M i c e
appeared well throughout treatment and did not experi-
ence any treatment related deaths.
Discussion
Pancreatic cancer is an aggressive disease and current
therapy is disappointing. Many tumors are inoperable at
the time of diagnosis, and recurrence is high in those
deemed operable. Therefore, many patients in clinical
trials have received chemotherapy or radiation therapy
in different treatment combinations, as neo-adjuvants or
as an adjuvant following surgery. While the technology
of therapeutic options has increased over the years, the
long-term survival rate has changed little over the past
few decades, stressing the need for more effective treat-
ments. We have shown that sigma-2 ligands increase
survival of tumor bearing mice and are additive to com-
bination regimens with chemotherapies. In this study,
we identified a novel sigma-2 ligand that has superior
efficacy in pancreatic cancer with limited offsite toxicity.
Chemotherapies and radiation are common in that
they disregulate the cell cycle directly or indirectly, and
activate apoptosis of tumor cells. Without specific tar-
geting of these treatments, systemic toxicities occur,
decreasing the therapeutic window. Compounds which
target sigma-2 receptors appear to be selective to
cancers. While, sigma-1 and sigma-2 receptors are
located in many normal tissues, sigma-2 receptors are
highly expressed in tumor cells, allowing selective target-
ing. We have also shown sigma-2 receptor ligands speci-
fically taken up in a mouse model of pancreas cancer by
micro PET/CT imaging [8]. This specificity may also
allow targeted therapy by the delivery of pro-apoptotic
molecules specifically to pancreatic cancer cells.
In this study, we identified a novel sigma-2 receptor
ligand that has superior efficacy in pancreatic cancer.
Multiple human and mouse pancreatic adenocarcinoma
cell lines were tested in vitro to asses the effect of our
compounds on viability. We showed that SW43 had a
greater capacity to decrease viability compared with
SV119 in all pancreas cancer cell lines tested, with an
IC50 value at least half that of SV119. Sigma-2 ligands
also had an additive effect with gemcitabine to induce
cell death. Cell death by SW43 occurs through a mechan-
ism consistent with apoptosis in pancreatic cancer cell
lines and induces caspase-3 activity even greater than our
previous compound SV119, though caspase-3 inhibitor
could not prevent cell death. The SW43 effect in vitro
was similar to that of siramesine, a widely studied sigma-
2 ligand. We verified that increased caspase-3 activity
correlated with induction of apoptosis by flow cytometry
for Annexin-V binding and the apoptotic effect was even
further increased by pre-treatment with gemcitabine.
We chose siramesine for comparison in our study
because it is an established sigma-2 ligand that has been
used in a phase I clinical trial as an anxiolytic [33].
Although siramesine did not meet the objective clinical
response in this trial, it was shown to be well tolerated
in 200 healthy volunteers. Following that trial, sirame-
sine has been tested in mice for the treatment of breast
cancer and was found to induce cytotoxicity mediated
in part by oxidative stress [28,32]. It was not determined
whether this effect was mediated by sigma-2 receptors
or by siramesine interactions in the membranes, though
siramesine has been recently shown to form high-affinity
complexes with phosphatidic acid [34].
The generation of reactive oxygen species (ROS) has
been well established to be a by-product as well as an
initiator of apoptosis and necrosis. Intracellular
Table 2 Viability of pancreas cancer cell lines following treatment with sigma-2 ligands and gemcitabine.
Gemcitabine - + - + - + - +
Cell Line DMSO SV119 SW43 SRM
Panc02 100 50 ± 3 79 ± 7 39 ± 1 24 ± 5 14 ± 2 6 ± 0 2 ± 2
Panc1 100 47 ± 5 81 ± 6 41 ± 5 43 ± 5 19 ± 4 8 ± 4 3 ± 3
BxPC3 100 71 ± 1 66 ± 2 52 ± 1 43 ± 4 33 ± 4 8 ± 2 2 ± 1
Cfpac 100 40 ± 8 88 ± 4 40 ± 4 60 ± 6 21 ± 7 8 ± 5 4 ± 2
Pancreas cancer cell lines were pretreated with gemcitabine (0.5 uM) or vehicle for 24 hours followed by sigma-2 ligand (25 uM) treatment for 18 hours and
viability represented as percentage relative to vehicle, (mean ± SEM), n ≥ 3.
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duction of ceramide or directly acting on the mitochon-
dria [35]. Depending on cell type, ROS have been shown
to increase mRNA and protein expression of pro-apop-
totic molecules such as FasL, FasR, Bax, and caspases-2
and -3, modulation of MAPK pathways, as well as
release of cytochrome c from the mitochondria [36,37].
Mechanisms of apoptosis by ROS are varied and may be
cell-type dependent.
We observed that SW43 induces ROS in pancreas
cancer cells and that apoptosis can be partially relieved
by treatment with the antioxidant alpha-tocopherol. In
contrast, apoptosis by siramesine induced ROS was
completely blocked by alpha-tocopherol, while SV119
generated little ROS. This suggests that the mechanism
of SW43 induced apoptosis is at least partially through
the generation of ROS. Based on the similar structure
and binding characteristics of SW43 and SV119, it is
plausible that they share an apoptotic pathway indepen-
dent of siramesine.
In Panc02 cells, binding affinity is high for sigma-2 and
low for sigma-1, with the relative affinity for sigma-2
ligands being SRM > SW43 = SV119. Increased binding
affinity of siramesine supports our data showing a lower
IC50 for viability than SW43 and SV119 and suggests that
sigma-2 receptor binding is important for initiation of
apoptosis. Binding affinity does not explain the lower IC50
for SW43 versus SV119 though. We speculate that the
extended aminoakyl chain of SW43 increases lipophilicity
and enhances membrane diffusion into the cell. Evidence
for membrane diffusion is supported by our previous stu-
dies showing that sigma-2 receptor ligand internalization
is only partially blocked with the well studied endocytosis
inhibitor phenylarsine oxide [38].
To verify that these promising in vitro results translate
into an anti-tumorigenic effect in vivo,w eu t i l i z e dt h e
aggressive Panc02 cell line in C57BL/6 mice. We have
shown that this treatment schedule resulted in minimal
toxicity in vivo that was well tolerated. Daily treatment
of sigma-2 ligands produced an effect statistically similar
to gemcitabine alone. Though SRM showed superior
efficacy in vitro, the results did not translate in our
in vivo model. SW43 combination therapy with gemcita-
bine resulted in the smallest tumor volume which had
stabilized during the two week treatment period. As
well, we demonstrate a therapeutic drug combination
that completely eradicated an established Panc02 tumor
in a C57BL/6 mouse, which we have not observed in
over a decade of our own experience. Survival was
increased for the combination of SW43 with gemcita-
bine from this treatment course. We expect that based
on the stabilization of tumor volume during the limited
treatment period (2 weeks), survival would be increased
if the treatment duration was lengthened.
Conclusions
We have shown that SW43 has high binding affinity for
sigma-2 binding sites in pancreatic cancer cell lines and
treatment of a variety of pancreas cancer cell lines with
SW43 showed higher cytotoxicity than our previous
compound SV119. As well, SW43 augmented the effects
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Figure 5 Sigma-2 ligands decrease Panc02 tumor burden in
C57BL/6. One million Panc02 cells were inoculated subcutaneously
into female, 10 week old C57BL/6 mice and when tumors had
reached a mean diameter of 5 mm, daily sigma-2 ligand treatment
with or without weekly gemcitabine began by IP injection. All
treatments decreased tumor volume compared to DMSO vehicle
alone, p < 0.001. A. Siramesine (SRM) treatment did not confer a
significantly different tumor volume than gemcitabine alone, *p >
0.05. Single agent sigma-2 ligands SV119 B. and SW43 C. decreased
tumor volume similar to gemcitabine, *p > 0.05, while combination
therapy produced much smaller tumors, **p < 0.001.
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here supports SW43 as the most promising sigma-2
ligand for clinical development in the treatment of pan-
creatic cancer.
Methods
Cell Culture
The human pancreas cancer cell lines BxPC3, AsPC1,
Cfpac, Panc1, and MiaPaCa-2 were obtained from
ATCC (Bethesda, MD). Murine pancreas adenocarci-
noma Panc02 was a gift from Bryan Clary (Duke
University). Panc02, AsPC1, and BxPC3 cells were
maintained in RPMI (GIBCO) supplemented with L-
glutamine (2 mM), HEPES (1 mM), pyruvate (1 mM),
sodium bicarbonate (0.0075% w/v); Cfpac in IMDM
containing L-glutamine (2 mM) and HEPES (25 mM);
Panc1 and MiaPaCa in DMEM (GIBCO) containing D-
glucose (4.5 g/L), L-glutamine (2 mM), HEPES (25
mM). All medias were supplemented with penicillin and
streptomycin (100 IU/mL), amphotericin (0.25 μg/mL),
and 10% FBS (Atlanta Biologicals, Lawrenceville, GA).
Cells were seeded at a concentration of 1.5 × 10
6/mL
unless otherwise noted and maintained in a humidified
atmosphere of 5% CO2 at 37°C.
Compounds
Sigma-2 ligands were synthesized as previously
described [28]. Chemical synthesis of these ligands is
based off a molecule with a 9-azabicyclo[39]nonoan-3b-
yl ring with an aminoalkyl extension (Figure 1A).
Sigma-2 selectivity is increased by greatly decreasing the
specificity to sigma-1 receptors [39]. SW43 is similar in
structure to SV119, with the aminoalkyl extension
lengthened from six carbons to ten carbons. [
125I]-ISO-2
was prepared by an iododestannylation reaction of the
corresponding tributyltin precursor [23]. The caspase-3
inhibitor Z-DEVD-FMK was obtained from R&D Sys-
tems (Minneapolis, MN); the caspase-3 cleavage sub-
strate Ac-DEVD-AMC from Bachem Biosciences, Inc
(King of Prussia, PA); gemcitabine from Eli Lilly and
Company (Indianapolis, IN). All other reagents were
obtained from Sigma (St Louis, MO) unless otherwise
stated. Sigma-2 ligands and inhibitors were dissolved in
DMSO and treatments in vitro and in vivo received
DMSO at a final concentration less than 0.3%.
Competitive binding analysis
Sigma-2 receptor competition was performed with
[
125I]-ISO-2, a benzamide analog of [
3H]-RHM-1, and
was used for this study due to higher specificity to
sigma-2-receptor ([
125I]-ISO-2, sigma-2 = 0.26 nM,
sigma-1 = 2,150 nM, sigma-1:sigma-2 ratio = 8,269)
compared to ([
3H]-RHM-1, sigma-2 = 10.3 nM, sigma-1
= 3078, sigma-1:sigma-2 ratio = 299) [23]. Membrane
homogenates were prepared from ~300 mg Panc02
tumor allografts, as previously described in our group
[8]. ~100 μg membrane homogenates were diluted with
50 mM Tris-HCl buffer, pH 8.0 and incubated with
~0.5 nM radioligand [
125I]-ISO-2 in a total volume of
150 µl at 25°C in 96 well polypropylene plates (Fisher
Scientific, Pittsburgh, PA). After incubation of 30 min,
the reactions were terminated by the addition of 150 µl
of cold wash buffer (10 mM Tris-HCl, 150 mM NaCl,
pH 7.4, at 4°C) using a 96 channel transfer pipette
(Fisher Scientific, Pittsburgh, PA), and the samples har-
vested and filtered rapidly to 96 well fiber glass filter
plate (Millipore, Billerica, MA). Each filter was washed
with 200 µl of ice-cold wash buffer for a total of three
washes. Then the filters were punched out and a Pack-
ard gamma counter (Beckman, Fullerton, CA) with a
counting efficiency of 75% for
125I was used to quanti-
tate the bound radioactivity. Nonspecific binding was
determined from samples which contained 10 µM
haloperidol.
Data from the competitive inhibition experiments
were modeled using nonlinear regression analysis to
determine the concentration of inhibitor that inhibits
50% (IC50) of the specific binding of the radioligand
(IC50 value). The competition curves were modeled for
a single site using the following equation:
BB BII C I s =− + () ⎡ ⎣ ⎤ ⎦ 0 05 0 */
Where Bs is the amount of the radioligand bound spe-
cifically to the membrane homogenates (i.e., Bs = Bt -
Bns,w h e r eBt is the total bound radioactivity and Bns is
the nonspecific binding of the radiotracer), B0 is the
amount of the radioligand bound in the absence of the
competitive inhibitor, Ii sthe concentration of the com-
petitive inhibitor and the IC50 is the concentration of
competitive inhibitor that blocks 50% of the total speci-
fic binding. The data analysis and curve fitting for IC50
were performed with the KaleidaGraph software pur-
chased from Synergy (Reading, PA) [22,23].
Detection of cell viability in vitro
Pancreas cancer cell lines maintained at optimal culture
conditions were seeded into 96 well plates the day prior
to treatment with escalating doses of the sigma-2 ligand.
Additionally, cells were pretreated with gemcitabine
(500 nM) for twenty four hours prior to sigma-2 ligand
treatment (25 μM). Eighteen hours after treatment, cell
viability was determined using the CellTiter-Glo Lumi-
nescent Viability Assay from Promega (Madison, WI).
This assay quantitates the number of metabolically
active cells by detecting ATP and gives a linear
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assay was conducted essentially as described by the
manufacturer and luminescence quantified using a Spec-
traMax Gemini microplate spectrofluorometer from
Molecular Devices (Silicon Valley, CA). Viability is
expressed relative to vehicle. Viability versus concentra-
tion of sigma-2 ligand was fit by non-linear regression
and the IC50 at 18 hours determined. Experiments were
conducted with duplicate wells and conducted at least
three times.
Detection of caspase-3 activity in vitro
Caspases are members of a family of cysteine proteases
with aspartate specificity that play a role in apoptosis.
The enzymatic substrate for caspase-3, found within
poly(ADP-ribose) polymerase (PARP), DEVD216-G217,
is utilized to observe activated caspase-3 by the libera-
tion of the fluorogenic molecule 7-amino-4-methylcou-
marin (AMC) from DEVD [40-42]. Murine pancreas
adenocarcinoma cell line Panc02 was maintained at
optimal culture conditions and seeded in 96 well plate
as above. The following day, cells were pretreated for
one hour with the caspase-3 inhibitor Z-DEVD-FMK (1
μM) or vehicle. Cells were then treated with sigma-2
ligands (25 μM) or vehicle and assayed 18 hours later.
A 5X assay buffer containing EDTA (10 mM), CHAPS
(5%), HEPES (100 mM), DTT (25 mM), and Ac-DEVD-
AMC (250 μM) was added directly to the cell media
and incubated for two hours at 37°C on a microplate
shaker before detection of liberated AMC. The fluores-
cence of AMC was detected using a SpectraMax Gemini
microplate spectrofluorometer, Molecular Devices (Sili-
con Valley, CA) with excitation at 355 nm and emission
at 450 nm.
Apoptosis detection by flow cytometry for Annexin-V
Annexin-V has a high affinity for phosphatidylserine and
is used as a marker of apoptosis [43]. Panc02 cells were
seeded into 12 well plates and the following day treated
with sigma-2 ligand (25 μM) or vehicle. Eighteen hours
later the cells were assayed using the Annexin-V FITC
Kit from Invitrogen Corporation (Camarillo, CA). The
cells were prepared as directed by the manufacturer and
analyzed with a FACSCalibur flow cytometer (BD Bios-
ciences, San Jose, CA).
Detection of reactive oxygen species by flow cytometry
Panc02 cells were seeded into 12-well plates one day prior
to treatment with sigma-2 ligand (25 μM). Eighteen hours
later cells were stained with 25 μM 5-(and-6)-carboxy-
2’,7’-dichlorodihydro-fluorescein diacetate (carboxy-
H2DCFDA) (Image-iT Live Green Reactive Oxygen
Species Detection Kit, Molecular Probes, Eugene, OR) for
30 minutes at 37°C and washed once with PBS before
analysis with a FACSCalibur flow cytometer (BD Bios-
ciences, San Jose, CA). The oxidation product of carboxy-
H2DCFDA to 2’,7’-dichlorofluorescein (DCF) fluoresceses
with an emmission maximum of 529 nm and was detected
in the FL1 channel.
Tumor growth, survival, and toxicity in vivo
In this pre-clinical model, we utilized the Panc02 cell line
[44], which is weakly immunogenic in C57BL/6 mice and
aggressive with a subcutaneous inoculum of 1 × 10
5 cells
being lethal within 6-8 weeks. Female, 10 week old
C57BL/6 mice, obtained from Harlan Laboratories, Inc
(Indianapolis, IN), were injected subcutaneously in the
right flank with 1 × 10
6 Panc02 cells suspended in 200
μL non-supplemented RPMI. When tumors had reached
approximately 5 mm in diameter, treatment began with
IP injection of DMSO or equimolar mass of the sigma-2
ligands SV119 (1 mg), SW43 (1.1 mg), or SRM (1.1 mg)
daily for two weeks, with or without once weekly gemci-
tabine (3 mg) for four weeks. Blood was collected from
several mice by intracardiac withdrawal for cytologic
(complete blood count) and biochemical analysis (AST,
ALT, BUN, Cr, amylase, and lipase) by the Washington
University Department of Comparative Medicine. Organs
were examined grossly and histologically. Tumors were
measured three times weekly with digital callipers and
the volume calculated using the equation V = d1(d2
2)/2,
(V = volume, d1= larger diameter, d2= smaller diameter).
A l lm i c ew e r ee u t h a n i z e dw h e nt u m o r sr e a c h e dad i a -
meter of 15 mm or had ulcerated. Studies were per-
formed in accordance with the animal studies protocol
approved by the Washington University Institutional
Animal Care Facility.
Statistical Analysis
The Washington University Division of Biostatistics was
consulted for statistical analysis. Data plotting and statis-
tical analysis was conducted using GraphPad Prism
(GraphPad Software, San Diego, CA). Data in figures
represent the mean ± SEM. Viability IC50 values at 18
hours were calculated by line fitting normalized viability
versus concentration with non-linear regression and sta-
tistical significance determined using one-way ANOVA.
Differences in viability, caspase-3 activity, apoptosis, and
oxidation status were analyzed using two-way ANOVA
to identify differences and confirmed with paired two-
tailed t-tests. Blood cytology and biochemistry results
were analyzed using one-way ANOVA with Tukey’s
multiple comparison test. Statistical analysis for the dif-
ference in tumor volume between treatments groups
was determined with the repeated measures ANOVA.
Kaplan-Meier survival curves were plotted and differ-
ences compared with a log-rank test. A p-value of less
than 0.05 was considered significant for all tests.
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Additional file 1: Sigma-2 ligands enhance gemcitabine induced
apoptosis evidenced by detection of Annexin-V by flow cytometry.
Panc02 cells were pre-treated with gemcitabine (500 nM) or vehicle for
24 hours prior to exposure to sigma-2 ligands (25 μM) or vehicle for 18
hours. Cells were then stained with Annexin-V-FITC conjugated antibody
and propidium iodide (PI) to be assessed by flow cytometry. Sigma-2
ligands induced apoptosis alone and enhanced gemcitabine induced
apoptosis. Annexin-V+/PI- represent early apoptotic cells and Annexin-V
+/PI+ cells show late apoptotic cells. Data is representative of triplicate
experiments.
Additional file 2: Blood cytology and serum chemistries for C57BL/6
mice treated daily with sigma-2 ligand and/or weekly gemcitabine
for 2 weeks. Blood cytology was analyzed for white blood count (CBC),
hemoglobin (HGB), and platelets (PLTS), while serum chemistries were
analyzed for the liver enzymes aspartate aminotransferase (AST) and
alanine aminotransferase (ALT), renally cleared metabolites blood urea
nitrogen (BUN) and creatinine (CR), as well as pancreatic enzymes
amylase and lipase. Of statistical and clinical significance was a decrease
in HGB in groups receiving combination treatment.
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